Earnings Per Share. Fiscal year 2008 adjusted diluted earnings per share* of $0.99, represents an increase of 87% compared to fiscal year 2007 adjusted diluted earnings per share of $0.53. Adjusted diluted earnings per share* for fiscal year 2008 excludes $11.4 million in net charges ($7.6 million in after-tax charges, or $0.61 per share tax effected), for the acceleration of stock awards, discontinuation of the Company's embolic protection platform, and sale of the Company's endovascular business. Adjusted diluted earnings per share* for fiscal year 2007 of $0.53 excludes $4.7 million in charges ($3.1 million in after-tax charges, or $0.25 per share tax effected) for the discontinuance of the Company's embolic protection platform. Including these items, reported diluted earnings per share for fiscal 2008 of $0.38, represents a 31% increase compared to fiscal year 2007 reported diluted earnings per share of $0.29.
* Diluted earnings per share excluding after-tax special charges are non-GAAP financial measures and should not be considered replacements for GAAP results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the accompanying table to this release.
In the fiscal year ended June 30, 2008, the total tax-effected impact
on earnings per share of equity compensation expense was $0.28, of which
$0.16 related to the acceleration of stock awards and $0.12 related to
equity compensation expense prior to the acceleration, equity compensation
|SOURCE Kensey Nash Corporation|
Copyright©2008 PR Newswire.
All rights reserved